iShares MSCI World ETF: A High-Stakes Balancing Act for Investors

iShares MSCI World ETF attracts heavy investment despite high fees, new US tariffs impacting healthcare and tech, and an upcoming major index methodology change.

Investors are pouring money into the iShares MSCI World ETF (URTH) at a breakneck pace, with nearly half a billion US dollars flowing in over just the last five trading days. This surge has pushed the fund's assets under management to approximately $7.5 billion. Yet this flood of capital arrives as the fund navigates a complex web of competitive, macroeconomic, and structural challenges that threaten to test investor loyalty.

The competitive landscape has shifted dramatically. Rivals have aggressively undercut the iShares fund on price. Invesco slashed the annual management fee for its $6.6 billion MSCI World UCITS ETF to 0.05% on April 1, following similar moves by UBS in May 2025 and BNP Paribas in September 2025. This leaves URTH's total expense ratio of 0.24% looking increasingly isolated, a point underscored by Morningstar in its latest review at the end of March. The rating agency maintained a Bronze rating but noted the fund could be more competitively priced.

Simultaneously, new macroeconomic headwinds are gathering force. The US administration has announced 100% tariffs on patented pharmaceutical imports, set to take effect in 120 days, with a reduced 15% rate for products from the EU, Japan, Korea, Switzerland, and Liechtenstein. Based on Section 232 of the Trade Expansion Act, these measures are considered more legally robust than previous tariffs largely deemed unconstitutional by the Supreme Court in February 2026. This policy directly impacts the ETF's health care sector.

The technology segment, which constitutes over 26% of the portfolio, is also in the crosshairs. Top holdings Nvidia, Apple, and Microsoft—which together account for 13.6% of the fund—are heavily reliant on Asian supply chains now under stress from trade tensions. Analysts estimate the new tariffs could add roughly 0.5 percentage points to global inflation, directly pressuring the profit margins of these giants. Investor anxiety was palpable on April 1, when trading volume spiked 26% to 654,315 shares.

Amid these pressures, a major structural change is on the horizon. In May 2026, MSCI will fundamentally alter its methodology for calculating free float. Because the March rebalancing was intentionally minimized, market observers anticipate a significantly higher portfolio turnover in May. Early signs of realignment were visible in Q1, with US equities seeing a net reduction for the first time in years and new positions like AST SpaceMobile and FTAI Aviation being added.

One potential source of selling pressure has been averted, however. MSCI has withdrawn its proposal to exclude companies with high crypto engagement from its core indices. The current treatment of firms where crypto assets make up 50% or more of total assets remains unchanged for now.

For now, institutional investors appear willing to overlook the cost disadvantage, seemingly valuing the fund's deep liquidity and brand recognition. The Royal Bank of Canada notably increased its position by 17.5% in Q4 2025, building a holding of around two million shares. The next test of this loyalty will come with the ex-dividend date on June 15, 2026, following a year of over 20% dividend growth. Whether the substantial capital inflows continue through the second quarter will be a crucial indicator of how investors weigh the fund's upcoming index overhaul and clear fee premium against its established market presence.